Oramed Pharmaceuticals Inc (ORMP) — Cash Flow Quality Index

Latest as of March 2026: -0.08x

Oramed Pharmaceuticals Inc (ORMP) has a Cash Flow Quality Index of -0.08x as of March 2026. Operating cash flow of $-2.92 Million is below net income of $38.31 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore ORMP cash flow conversion to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.08x
Operating CF / Net Income

Operating Cash Flow

$-2.92 Million
USD

Net Income

$38.31 Million
USD

Data as of

Mar 2026
Most recent filing

Oramed Pharmaceuticals Inc Cash Flow Quality Index (2023–2025)

Historical Cash Flow Quality Index for Oramed Pharmaceuticals Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check ORMP total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Oramed Pharmaceuticals Inc (2023–2025)

Year-by-year earnings quality comparison for Oramed Pharmaceuticals Inc. For live market cap and the full company financial profile, see market value of Oramed Pharmaceuticals Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2025 -0.14x $-9.14 Million $64.02 Million ▲ +92.3%
2023 -1.86x $-10.29 Million $5.53 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.